羟氯喹治疗住院Covid-19患者的疗效
本研究为随机、对照、开放标签平台试验,比较多种可能治疗与常规治疗在住院Covid-19患者中的效果。共随机分配1561例至羟氯喹组、3155例至常规治疗组,主要终点为28天死亡率。中期分析确定无效后,羟氯喹组入组于2020年6月5日停止。28天死亡:羟氯喹组421例(27.0%)vs 常规治疗组790例(25.0%)(率比1.09;95%CI 0.97-1.23;P=0.15),所有预设亚组结果一致。羟氯喹组28天内活出院可能性更低(59.6% vs 62.9%;率比0.90;95%CI 0.83-0.98)。基线未行机械通气者中,羟氯喹组有创机械通气或死亡频率更高(30.7% vs 26.9%;风险比1.14;95%CI 1.03-1.27)。
要点
- 住院Covid-19患者中,羟氯喹组28天死亡率27.0% vs 常规治疗组25.0%,率比1.09(95%CI 0.97-1.23;P=0.15),无显著差异。
- 所有预设亚组结果一致,提示羟氯喹在各亚组中均未显示降低28天死亡率。
- 羟氯喹组28天内活出院率59.6% vs 常规治疗组62.9%,率比0.90(95%CI 0.83-0.98),羟氯喹组更低。
- 基线未行机械通气者中,羟氯喹组有创机械通气或死亡30.7% vs 常规治疗组26.9%,风险比1.14(95%CI 1.03-1.27)。
- 羟氯喹组心脏死亡有小幅数值超额(0.4个百分点),但新发重大心脏心律失常发生率无差异。
适用人群与场景
- 住院Covid-19患者,随机分配1561例至羟氯喹组、3155例至常规治疗组。
- 基线未行机械通气者纳入有创机械通气或死亡的次要分析(羟氯喹组 vs 常规治疗组)。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 羟氯喹组接受羟氯喹治疗,常规治疗组接受常规治疗;原文未提及羟氯喹剂量、给药途径、频次或疗程。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机、对照、开放标签平台试验;样本量:羟氯喹组1561例、常规治疗组3155例;人群:住院Covid-19患者;干预:羟氯喹 vs 常规治疗;主要终点28天死亡率:羟氯喹组27.0% vs 常规治疗组25.0%(率比1.09;95%CI 0.97-1.23;P=0.15)。
- 所有预设亚组结果一致。
- 28天内活出院:羟氯喹组59.6% vs 常规治疗组62.9%(率比0.90;95%CI 0.83-0.98)。
- 基线未行机械通气者中有创机械通气或死亡:羟氯喹组30.7% vs 常规治疗组26.9%(风险比1.14;95%CI 1.03-1.27)。
- 心脏死亡:羟氯喹组有小幅数值超额(0.4个百分点);新发重大心脏心律失常发生率无差异。
- 中期分析确定无效后,羟氯喹组入组于2020年6月5日停止。
证据类型、等级与局限
- 证据类型:随机、对照、开放标签平台试验。
- 原文未述局限性。
对床旁实践的改变
- 住院Covid-19患者中,羟氯喹未降低28天死亡率,且28天内活出院率更低、基线未行机械通气者有创机械通气或死亡频率更高。
- 原文未提及适用与不适用人群的进一步限定。
指南或共识出处
- RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936;资助:UK Research and Innovation and National Institute for Health Research and others。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.
METHODS: In this randomized, controlled, open-label platform trial comparing a range of possible treatments with usual care in patients hospitalized with Covid-19, we randomly assigned 1561 patients to receive hydroxychloroquine and 3155 to receive usual care. The primary outcome was 28-day mortality.
RESULTS: The enrollment of patients in the hydroxychloroquine group was closed on June 5, 2020, after an interim analysis determined that there was a lack of efficacy. Death within 28 days occurred in 421 patients (27.0%) in the hydroxychloroquine group and in 790 (25.0%) in the usual-care group (rate ratio, 1.09; 95% confidence interval [CI], 0.97 to 1.23; P = 0.15). Consistent results were seen in all prespecified subgroups of patients. The results suggest that patients in the hydroxychloroquine group were less likely to be discharged from the hospital alive within 28 days than those in the usual-care group (59.6% vs. 62.9%; rate ratio, 0.90; 95% CI, 0.83 to 0.98). Among the patients who were not undergoing mechanical ventilation at baseline, those in the hydroxychloroquine group had a higher frequency of invasive mechanical ventilation or death (30.7% vs. 26.9%; risk ratio, 1.14; 95% CI, 1.03 to 1.27). There was a small numerical excess of cardiac deaths (0.4 percentage points) but no difference in the incidence of new major cardiac arrhythmia among the patients who received hydroxychloroquine.
CONCLUSIONS: Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care. (Funded by UK Research and Innovation and National Institute for Health Research and others; RECOVERY ISRCTN number, ISRCTN50189673; ClinicalTrials.gov number, NCT04381936.).
参考来源
- Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020. PMID: 33031652. doi:10.1056/NEJMoa2022926
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。